
HTA Agencies Meeting Updates: It seems the Heads of HTA Agencies Group had a productive meeting in Lisbon, Portugal. They discussed key strategic topics including the confirmation of the new Vice-Chair, updates on the HTA Regulation and long-term strategic planning for the group!
Next meeting will take place in Stockholm, Sweden in May 2023.
Recent Posts

Orphan Drug Designation Zoci Enhances Treatment Prospects for Pulmonary Neuroendocrine Carcinomas
The European Medicines Agency has granted orphan drug designation for zocilurtatug pelitecan, an investigational DLL3-targeted antibody-drug conjugate, based on ...

Belgium Fast Access Medicines Revolutionize Treatment for IgA Nephropathy
Belgium Fast Access Medicines has moved from policy to practice. Authorities have granted temporary reimbursement to Atrasentan, the first therapy approved under the new Early and Equitable Fast Access procedure, offering quicker hope to patients with IgA nephropathy while anchoring the country’s...

Retracted Trial Publication Undermines Support for Avacopan in AAV Treatment
The Retracted Trial Publication of the ADVOCATE study has eliminated the central evidence that supported approval of Tavneos (avacopan) for severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (AAV). At the request of two lead academic authors, the